Cargando…
Factors Associated With Weight Gain in People Treated With Dolutegravir
BACKGROUND: An unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens. METHODS: Adult naïve and experienced people with HIV (PWH) in...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295329/ https://www.ncbi.nlm.nih.gov/pubmed/32577427 http://dx.doi.org/10.1093/ofid/ofaa195 |
_version_ | 1783546629524029440 |
---|---|
author | Taramasso, Lucia Bonfanti, Paolo Ricci, Elena Orofino, Giancarlo Squillace, Nicola Menzaghi, Barbara De Socio, Giuseppe Vittorio Madeddu, Giordano Pellicanò, Giovanni Francesco Pagnucco, Layla Celesia, Benedetto Maurizio Calza, Leonardo Conti, Federico Martinelli, Canio Vito Valsecchi, Laura Cascio, Antonio Bolla, Cesare Maggi, Paolo Vichi, Francesca Dentone, Chiara Angioni, Goffredo Mastroianni, Antonio Falasca, Katia Cenderello, Giovanni Di Biagio, Antonio |
author_facet | Taramasso, Lucia Bonfanti, Paolo Ricci, Elena Orofino, Giancarlo Squillace, Nicola Menzaghi, Barbara De Socio, Giuseppe Vittorio Madeddu, Giordano Pellicanò, Giovanni Francesco Pagnucco, Layla Celesia, Benedetto Maurizio Calza, Leonardo Conti, Federico Martinelli, Canio Vito Valsecchi, Laura Cascio, Antonio Bolla, Cesare Maggi, Paolo Vichi, Francesca Dentone, Chiara Angioni, Goffredo Mastroianni, Antonio Falasca, Katia Cenderello, Giovanni Di Biagio, Antonio |
author_sort | Taramasso, Lucia |
collection | PubMed |
description | BACKGROUND: An unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens. METHODS: Adult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for weight increases >10% from baseline. RESULTS: A total of 713 participants, 25.3% women and 91% Caucasian, were included. Of these, 195 (27.4%) started DTG as their first ART regimen, whereas 518 (72.6%) were ART-experienced. DTG was associated with abacavir/lamivudine in 326 participants, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 148, boosted protease inhibitors in 60, rilpivirine in 45, lamivudine in 75, and tenofovir alafenamide (TAF)/FTC in 59. At 6 and 12 months, weight gain was highest among PWH on TDF/FTC+DTG and TAF/FTC+DTG. Baseline CD4 <200 cells/mm(3) (HR, 1.84; 95% CI, 1.15 to 2.96), being ART-naïve (HR, 2.24; 95% CI, 1.24 to 4.18), and treatment with TDF/FTC+DTG (HR, 1.92; 95% CI, 1.23 to 2.98) or TAF/FTC+DTG (HR, 3.80; 95% CI, 1.75 to 8.23) were associated with weight gain >10% from baseline. Higher weight (HR, 0.97 by 1 kg; 95% CI, 0.96 to 0.99) and female gender (HR, 0.54; 95% CI, 0.33 to 0.88) were protective against weight gain. CONCLUSIONS: Naïve PWH with lower CD4 counts and those on TAF/FTC or TDF/FTC backbones were at higher risk of weight increase in the course of DTG-based ART. |
format | Online Article Text |
id | pubmed-7295329 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72953292020-06-22 Factors Associated With Weight Gain in People Treated With Dolutegravir Taramasso, Lucia Bonfanti, Paolo Ricci, Elena Orofino, Giancarlo Squillace, Nicola Menzaghi, Barbara De Socio, Giuseppe Vittorio Madeddu, Giordano Pellicanò, Giovanni Francesco Pagnucco, Layla Celesia, Benedetto Maurizio Calza, Leonardo Conti, Federico Martinelli, Canio Vito Valsecchi, Laura Cascio, Antonio Bolla, Cesare Maggi, Paolo Vichi, Francesca Dentone, Chiara Angioni, Goffredo Mastroianni, Antonio Falasca, Katia Cenderello, Giovanni Di Biagio, Antonio Open Forum Infect Dis Major Article BACKGROUND: An unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens. METHODS: Adult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for weight increases >10% from baseline. RESULTS: A total of 713 participants, 25.3% women and 91% Caucasian, were included. Of these, 195 (27.4%) started DTG as their first ART regimen, whereas 518 (72.6%) were ART-experienced. DTG was associated with abacavir/lamivudine in 326 participants, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 148, boosted protease inhibitors in 60, rilpivirine in 45, lamivudine in 75, and tenofovir alafenamide (TAF)/FTC in 59. At 6 and 12 months, weight gain was highest among PWH on TDF/FTC+DTG and TAF/FTC+DTG. Baseline CD4 <200 cells/mm(3) (HR, 1.84; 95% CI, 1.15 to 2.96), being ART-naïve (HR, 2.24; 95% CI, 1.24 to 4.18), and treatment with TDF/FTC+DTG (HR, 1.92; 95% CI, 1.23 to 2.98) or TAF/FTC+DTG (HR, 3.80; 95% CI, 1.75 to 8.23) were associated with weight gain >10% from baseline. Higher weight (HR, 0.97 by 1 kg; 95% CI, 0.96 to 0.99) and female gender (HR, 0.54; 95% CI, 0.33 to 0.88) were protective against weight gain. CONCLUSIONS: Naïve PWH with lower CD4 counts and those on TAF/FTC or TDF/FTC backbones were at higher risk of weight increase in the course of DTG-based ART. Oxford University Press 2020-05-26 /pmc/articles/PMC7295329/ /pubmed/32577427 http://dx.doi.org/10.1093/ofid/ofaa195 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Taramasso, Lucia Bonfanti, Paolo Ricci, Elena Orofino, Giancarlo Squillace, Nicola Menzaghi, Barbara De Socio, Giuseppe Vittorio Madeddu, Giordano Pellicanò, Giovanni Francesco Pagnucco, Layla Celesia, Benedetto Maurizio Calza, Leonardo Conti, Federico Martinelli, Canio Vito Valsecchi, Laura Cascio, Antonio Bolla, Cesare Maggi, Paolo Vichi, Francesca Dentone, Chiara Angioni, Goffredo Mastroianni, Antonio Falasca, Katia Cenderello, Giovanni Di Biagio, Antonio Factors Associated With Weight Gain in People Treated With Dolutegravir |
title | Factors Associated With Weight Gain in People Treated With Dolutegravir |
title_full | Factors Associated With Weight Gain in People Treated With Dolutegravir |
title_fullStr | Factors Associated With Weight Gain in People Treated With Dolutegravir |
title_full_unstemmed | Factors Associated With Weight Gain in People Treated With Dolutegravir |
title_short | Factors Associated With Weight Gain in People Treated With Dolutegravir |
title_sort | factors associated with weight gain in people treated with dolutegravir |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295329/ https://www.ncbi.nlm.nih.gov/pubmed/32577427 http://dx.doi.org/10.1093/ofid/ofaa195 |
work_keys_str_mv | AT taramassolucia factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT bonfantipaolo factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT riccielena factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT orofinogiancarlo factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT squillacenicola factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT menzaghibarbara factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT desociogiuseppevittorio factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT madeddugiordano factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT pellicanogiovannifrancesco factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT pagnuccolayla factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT celesiabenedettomaurizio factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT calzaleonardo factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT contifederico factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT martinellicaniovito factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT valsecchilaura factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT cascioantonio factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT bollacesare factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT maggipaolo factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT vichifrancesca factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT dentonechiara factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT angionigoffredo factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT mastroianniantonio factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT falascakatia factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT cenderellogiovanni factorsassociatedwithweightgaininpeopletreatedwithdolutegravir AT dibiagioantonio factorsassociatedwithweightgaininpeopletreatedwithdolutegravir |